OKYO Stock Forecast & Price Target

OKYO Pharma Ltd is showing strong progress in the clinical development of its drug, urcosimod, which has demonstrated significant efficacy in pain reduction for patients. Notably, 67% of patients receiving the 0.05% formulation reported over 50% improvement in pain, markedly outperforming the 33% in the placebo group, with effects being observed as early as Week 4. These promising clinical results point to a positive trajectory for the company’s therapeutic offerings in the inflammatory eye disease and chronic pain markets, supporting a favorable outlook for the stock.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year ending March 31, 2025, equating to a loss of $0.12 per share, which raises concerns about the company's financial stability. Additionally, the clinical trial results for their 0.05% urcosimod indicated a significant disparity in baseline pain scores between treatment and placebo groups, suggesting potential challenges in efficacy and patient outcomes. The company faces several substantial risks, including the possibility of clinical trial failures, regulatory hurdles, and commercial viability challenges, which collectively contribute to a negative outlook on its stock performance.